Abbott feels sting of shrinking DES (drug-eluting stent) market; cuts 1,200 jobs
This article was originally published in Clinica
Executive Summary
Another big hitter has buckled under the pressures of a weakening drug-eluting stent (DES) market, with Abbott revealing on Tuesday (December 5) it was axing 1,200 jobs at two facilities that manufacture vascular products.